Skip to main content

Drug Interactions between dihydrocodeine / guaifenesin and Kola-Pectin DS

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

bismuth subsalicylate dihydrocodeine

Applies to: Kola-Pectin DS (bismuth subsalicylate) and dihydrocodeine / guaifenesin

Using bismuth subsalicylate together with dihydrocodeine can increase the blood levels or add to the side effects of either medication. Talk with your doctor before using these medications together. Call the doctor if you have side effects such as extreme drowsiness, dizziness, weak pulse, slow heart rate, sweating, urinating less than usual, severe stomach cramps or bloating, and vomiting. You should avoid activities requiring mental alertness until you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.